Systemic lupus erythematosus (SLE) is a complex immune disorder in which loss of
tolerance to nucleic acid antigens and other cross‐reactive antigens is associated with the …

BAFF (BLyS) and APRIL are TNF-like cytokines that support survival and differentiation of B
cells. Recent studies have discovered a role for BAFF in augmenting both innate and …

Given the prominent role currently assigned to B lymphocytes in systemic lupus
erythematosus, it is not surprising that the B cell activity factor belonging to the tumor …

BAFF and APRIL are TNF-like cytokines that support survival and differentiation of B cells.
The early appreciation that overexpression of BAFF leads to B cell expansion and a lupus …

Introduction: The anti-BAFF monoclonal antibody, belimumab, was approved 5+ years ago
by the US Food and Drug Administration for the treatment of adult SLE patients. Although …

B cells have multiple roles in immune activation and inflammation separate from their
capacity to produce antibodies. B cell depletion is currently under intense investigation as a …

Recently, the B cell has emerged as a cornerstone of systemic lupus erythematosus (SLE)
pathogenesis. This has been highlighted by studies of the cytokine B‐cell‐activating factor of …

BAFF (B lymphocyte activating factor of the tumour necrosis factor family) is a vital
homeostatic cytokine for B cells that helps regulate both innate and adaptive immune …

It is increasingly recognized that B cells have multiple functions that contribute to the
pathogenesis of autoimmunity. Specific targeting of B cells might therefore be an appropriate …

B-cell activating factor (BAFF), a member of the family of TNF-like cytokines, supports the
survival and differentiation of B cells. The successful development of belimumab, a human …